Neo-adjuvant therapy with dose-dense XXXX plus short-term filgrastim rescue for locally advanced @entity0 .

@entity1 @entity632 @entity9962 @entity137 @entity1261 @entity0 @entity440 @entity5 @entity221 @entity786 @entity3 @entity158 @entity1205 @entity356
Neo-adjuvant, dose-dense @entity1205 , 100 mg/m(2) every 2 weeks x 4 cycles, was administered to 12 @entity1 with locally advance @entity0 (LABC) (10 stage IIIa and three stage IIIb). Eligibility requirements included a PS 0-2, normal hepatic and renal function, and radiologic absence of @entity3 . Filgrastim [ @entity1261 ( @entity1261 )] was started 1 day after chemotherapy and was given for 6 days. Complete blood counts were determined weekly. Surgery was planned upon recovery from the last dose of @entity1205 and followed by 4 cycles of adjuvant @entity632 plus @entity786 (AC) and radiotherapy. @entity1 with ER status received @entity440 . The median age was 45 (range 34-73) and pre-treatment pathology revealed poorly differentiated @entity9962 in 11 and @entity356 in one, with positive ER/PR status in five. Twelve @entity1 were treated, and all are evaluable for response and @entity137 . Nine @entity1 had a major clinical @entity5 response with five PR and four pathologic complete responses (pCR rate of 33%). Three @entity1 (of whom two with stage IIIb) had progressive disease and went on to receive neo-adjuvant therapy with AC. There was one instance of grade 3 hematologic @entity137 ( @entity221 in one @entity1261 non-compliant @entity1 ). There were two instances of grade 3 extra-hematologic @entity137 : one @entity1 had severe @entity158 and one had treatment-related fatigue. After a median follow-up of 20 months (range 7-49 months) all @entity1 are alive and eight of nine responders remain progression-free. Despite the small size of our study, we believe that dose-dense neo-adjuvant @entity1205 is well tolerated and its activity warrants confirmation in a larger number of @entity1 .
